ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

AnGes, Inc.

Business Summary

AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.

Financial Highlights

Dec 2021 JPYUSD
Revenue64.14M0.58M
Gross Profit-2,410.09M-21.93M
Operating income-15,632.08M-142.27M
Income before tax-13,735.29M-125.01M
Net income-13,675.58M-124.46M
EBITDA-13,206.00M-120.19M
Diluted EPS-92.85-0.84
Dividends Per Share00
Total Assets45,455.74M394.73M
Total liabilities6,821.00M59.23M
Total equity38,634.74M335.50M
Operating cash flow-11,380.54M-103.57M
Currency in JPYCurrency in USD

Historical Data

 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 365.18M 610.05M 326.75M 39.99M 64.14M
Gross Profit 163.69M 418.87M 235.16M 12.06M -2,410.09M
Operating income -3,288.68M -3,065.25M -3,270.00M -5,599.39M -15,632.08M
Income before tax -3,744.18M -3,003.00M -3,751.60M -4,204.95M -13,735.29M
Net income -3,764.69M -2,996.62M -3,750.82M -4,209.51M -13,675.58M
EBITDA -3,259.32M -3,057.39M -3,262.68M -5,591.80M -13,206.00M
Diluted EPS -49.38 -34.46 -35.81 -35.32 -92.85
Dividends Per Share 0 0 0 0 0
Total Assets 3,963.60M 8,050.67M 12,524.60M 38,354.61M 45,455.74M
Total liabilities 341.72M 316.21M 469.24M 5,674.93M 6,821.00M
Total equity 3,621.88M 7,734.45M 12,055.35M 32,679.67M 38,634.74M
Operating cash flow -2,991.22M -2,522.50M -2,179.91M -2,961.32M -11,380.54M
 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 3.25M 5.52M 2.99M 0.37M 0.58M
Gross Profit 1.45M 3.79M 2.15M 0.11M -21.93M
Operating income -29.32M -27.75M -29.99M -52.44M -142.27M
Income before tax -33.39M -27.19M -34.41M -39.38M -125.01M
Net income -33.57M -27.13M -34.40M -39.42M -124.46M
EBITDA -29.06M -27.68M -29.92M -52.37M -120.19M
Diluted EPS -0.44 -0.31 -0.32 -0.33 -0.84
Dividends Per Share 0 0 0 0 0
Total Assets 35.18M 73.37M 115.24M 371.49M 394.73M
Total liabilities 3.03M 2.88M 4.31M 54.96M 59.23M
Total equity 32.15M 70.49M 110.93M 316.52M 335.50M
Operating cash flow -26.67M -22.83M -19.99M -27.73M -103.57M

Valuation Measures

Dec 2021
PER--
ROA-32.63%
ROE-38.35%
Operating margin-24,368.77%
Profit margin-21,318.80%

Key executives

  • President & Representative Director: Ei Yamada
  • Director, Executive Officer & Manager-Finance: Tetsuji Yoneo
  • Director & Manager-Drug Discovery Research: Kazuo Suzuki
  • Executive Officer, Manager-R&D Promotion: Hajime Watanabe
  • Manager-Accounting: Jun Sakurai

Shareholders

  • OrbiMed Advisors Private Equity (3.8%)
  • BlackRock Fund Advisors (1.3%)
  • Shionogi & Co., Ltd. (0.7%)
  • MORISHITA RYUICHI (0.4%)
  • BlackRock Advisors (UK) Ltd. (0.2%)
  • TIAA-CREF Investment Management LLC (0.1%)
  • SSgA Funds Management, Inc. (0.0%)
  • Geode Capital Management LLC (0.0%)
  • Credit Suisse Asset Management (Schweiz) AG (0.0%)
  • ISHIHARA SANGYO KAISHA LTD. (0.0%)

Contact Details

  • Website:http://www.anges.co.jp
  • Address: Saito Bio-Incubator, 1/F, 7-7-15 Saito-Asagi, Osaka, 567-0085, Japan
  • Phone: +81.72.643.3590

Related Companies

  • Emendo Biotherapeutics, Inc.
  • AnGes USA, Inc.
  • AnGes Euro Ltd.

Competitors

  • Sienna Biopharmaceuticals, Inc.
  • Athira Pharma, Inc.
Last Updated on 24 May, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more